

<b>TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT</b> (Under 37 CFR 1.97(b) or 1.97(c))			Docket No. Army 126	
In Re Application Of:    Meyerhoff, et al.				
Serial No. 09/692,938	Filing Date October 20, 2000	Examiner unknown	Group Art Unit 1614	
Title:    Pharmaceutical Composition Containing PGLU-GLU-Pro and Method For Treating Diseases and Injuries to the Brain, Spinal Cord and Retina Using Same				
COPY OF PAPERS ORIGINALLY FILED				
<b>RECEIVED</b>				
<div style="text-align: center;">             Address to:  <b>Assistant Commissioner for Patents</b>              Washington, D.C. 20231           </div> <div style="text-align: right; margin-top: 10px;"> <b>MAR - 4 2002</b>  <b>TECH CENTER 1600/2900</b> </div> <div style="text-align: center; margin-top: 20px;"> <b>37 CFR 1.97(b)</b> </div> <p>1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.</p> <div style="text-align: center; margin-top: 20px;"> <b>37 CFR 1.97(c)</b> </div> <p>2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</p> <div style="margin-left: 40px;"> <input type="checkbox"/> the statement specified in 37 CFR 1.97(e);         </div> <div style="text-align: center; margin: 10px 0;"> <b>OR</b> </div> <div style="margin-left: 40px;"> <input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).         </div>				

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
Army 126

In Re Application: Meyerhoff, et al.

Serial No.  
09/692,938

Filing Date  
October 20, 2000

Examiner  
unknown

Group Art Unit  
1614

Pharmaceutical Composition Containing PGLU-GLU-Pro and method for treating Diseases and  
to the Brain, Spinal Cord and Retina Using Same

COPY OF PAPERS  
ORIGINALLY FILED

RECEIVED

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 21-0380 as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of \_\_\_\_\_
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F \_\_\_\_\_)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited  
February 12, 2002 with the U.S. Postal Service  
as first class mail under 37 C.F.R. 1.8 and is  
addressed to the Assistant Commissioner for Patents,  
Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Caroline Nash

Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.

*Caroline Nash*

Signature

Dated: February 12, 2002

Caroline Nash, Reg. No. 36,329

Nash & Titus, LLC

3415 Brookeville Road

Brookeville, MD 20833

301 924-9500

for: Elizabeth Arwine, Reg. No. 45,867

U.S. Army Medical Research and Materiel Command

CC: